Clinical Trial Update: SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial update for SHR1459 in combination with YY-20394 in recurrent and refractory B-cell non-Hodgkin's lymphoma is listed, with status unspecified.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• SHR1459
• YY-20394

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma | Phase 2 | Status: UNKNOWN